Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
92 hedge funds and large institutions have $62.4M invested in Sorrento Therapeutics, Inc. in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 39 increasing their positions, 16 reducing their positions, and 14 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 16
73% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $1.32M
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
5% more funds holding
Funds holding: 88 → 92 (+4)
42% less capital invested
Capital invested by funds: $107M → $62.4M (-$44.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.88M |
| 2 |
Goldman Sachs
New York
|
+$2.34M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$1.15M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$749K |
| 5 |
JP Morgan Chase
New York
|
+$690K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.51M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.08M |
| 3 |
AMG
Advisors Management Group
La Crosse,
Wisconsin
|
-$669K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$459K |
| 5 |
Morgan Stanley
New York
|
-$396K |
SRNE Hedge Fund Activity: Q1 2020 in Review
92 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2020, worth a combined $62.4M — down 42% from $107M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SRNE positions and 14 closed out — a net gain of 7 holders — while 39 added to existing stakes and 16 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $2.88M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $1.51M sold.
- 92 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2020, up from 88 in Q4 2019.
- Funds reported $62.4M of Sorrento Therapeutics, Inc. stock for Q1 2020, down 42% quarter-over-quarter.
- 21 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2020 and 14 closed out, a net change of +7 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2020 was Cormorant Asset Management, an estimated $2.88M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2020 was Rubric Capital Management (New York), an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2020.